| 今开：1.84 | 昨收：1.84 |
| 最高：1.9 | 最低：1.82 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：3.7243152E7 |
Fortress Biotech(FBIO)04-06 05:35
$Fortress Biotech(FBIO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001558370-24-004792 Act: 34 Size: 485 KB 网页链接查看全文
Fortress Biotech(FBIO)03-23 06:25
$Fortress Biotech(FBIO)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-037987 Size: 50 KB 网页链接查看全文
Fortress Biotech(FBIO)05-16 04:45
$Fortress Biotech(FBIO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-008299 Act: 34 Size: 11 MB 网页链接查看全文
Fortress Biotech(FBIO)04-06 05:25
$Fortress Biotech(FBIO)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001104659-24-044358 Act: 33 Size: 9 KB 网页链接查看全文
Fortress Biotech(FBIO)04-06 05:35
$Fortress Biotech(FBIO)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-24-004791 Act: 34 Size: 1 MB 网页链接查看全文
Fortress Biotech(FBIO)05-18 01:25
$Fortress Biotech(FBIO)$ 144 Report of proposed sale of securities Accession Number: 0001971857-24-000242 Act: 33 Size: 4 KB 网页链接查看全文
Fortress Biotech(FBIO)03-23 06:25
$Fortress Biotech(FBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-037986 Act: 34 Size: 5 KB 网页链接查看全文
Fortress Biotech(FBIO)05-21 05:05
$Fortress Biotech(FBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-063455 Size: 4 KB 网页链接查看全文
Fortress Biotech(FBIO)05-21 05:05
$Fortress Biotech(FBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-063451 Size: 4 KB 网页链接查看全文
Fortress Biotech(FBIO)04-03 04:15
$Fortress Biotech(FBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-042504 Size: 5 KB 网页链接查看全文
美股滚雪球2023-04-25 14:36
$4D Molecular(FDMT)$ 收购了Aevitas Therapeutics用于治疗补体介导疾病的短形式人补体因子H (sCFH)资产的全球权利。
根据协议，4D将向$Fortress Biotech(FBIO)$ 旗下子公司Aevitas支付总计1.4亿美元，用于潜在的后期开发、监管和销售里程碑，以及销售特许权使用费。
两家公司表示，这笔款...查看全文
美股滚雪球2021-11-16 16:05
别人是卖药赚钱，$Fortress Biotech(FBIO)$ 是卖公司：阿斯利康收购了它的子公司Caelum Biosciences，收到预付款5690万美元，又一家子公司Journey Medical Corporation准备IPO。$恒瑞医药(SH600276)$ $长春高新(SZ000661)$查看全文
美股滚雪球2021-09-30 10:25
$Fortress Biotech(FBIO)$ 因阿斯利康名下的ALXN并购了自己的子公司Caelum而大涨，FBIO有望获得6400万美元，这是文中介绍的积极抓住子公司资产的合作、出售等商业化机会。 $恒瑞医药(SH600276)$ $沃森生物(SZ300142)$查看全文
美股滚雪球2021-06-07 09:59
本文摘要：
1、Hub-and-Spoke模式为何在创新药行业兴起？
2、Hub-and-Spoke模式的优点和缺点有哪些？
3、Hub-and-Spoke模式的案例分析
$Centessa(CNTA)$ $BridgeBio Pharma(BBIO)$ $Fortress Biotech(FBIO)$查看全文
美股律师郝俊波2020-12-01 17:43
$Fortress Biotech(FBIO)$ 【 Fortress Biotech Inc最新证券诉讼 】
Fortress Biotech Inc (FBIO)因证券欺诈案已经于近日被投资者诉至法院。在目前的诉讼中投资者指控该公司在2019年12月11日至2020年10月9日期间就公司的业务运营状况和合规政策进行虚假陈述，为向投资者披露以下重大不利事实...查看全文
$Fortress Biotech(FBIO)$ 8-K - Current report Filed: 2019-05-10 AccNo: 0001144204-19-025266 Size: 111 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Fortress Biotech(FBIO)$ DEF 14A - Other definitive proxy statements Filed: 2019-04-30 AccNo: 0001144204-19-022105 Size: 1 MB 网页链接
$Fortress Biotech(FBIO)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-04-30 AccNo: 0001144204-19-022108 Size: 450 KB 网页链接
$Fortress Biotech(FBIO)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-04-19 AccNo: 0001144204-19-020405 Size: 58 KB 网页链接
$Fortress Biotech(FBIO)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-04-19 AccNo: 0001144204-19-020407 Size: 64 KB 网页链接
$Fortress Biotech(FBIO)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-04-19 AccNo: 0001144204-19-020408 Size: 64 KB 网页链接
$Fortress Biotech(FBIO)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-03-18 AccNo: 0001144204-19-014617 Size: 24 MB 网页链接
$Fortress Biotech(FBIO)$ 8-K - Current report Filed: 2019-03-18 AccNo: 0001144204-19-014679 Size: 170 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Fortress Biotech(FBIO)$ 8-K - Current report Filed: 2019-02-15 AccNo: 0001144204-19-008647 Size: 424 KBItem 2.01: Completion of Acquisition or Disposition of AssetsItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Fortress Biotech(FBIO)$ 8-K - Current report Filed: 2019-02-11 AccNo: 0001144204-19-005992 Size: 25 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接